Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax COIN Option Income Strategy ETF vs Zimmer Biomet Holdings Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.11, while Zimmer Biomet Holdings Inc trades at $96.41 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while YieldMax COIN Option Income Strategy ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, YieldMax COIN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| CONY | ZBH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $76.50 | $107.71 |
52-Week Low | $17.80 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONY trades at $18.11, up 0.22% on the day, with a bearish technical signal driven by moving averages. The ETF shows no available valuation or profitability ratios, and recent news highlights weekly dividend distributions but also concerns over shareholder losses and declining value despite high yields. Technical indicators show RSI near oversold levels at 29.18, suggesting potential for a rebound, while resistance sits at $19.
The outlook remains cautious due to bearish technicals and negative media sentiment questioning sustainability. Risks include reliance on options income and market volatility. Analyst coverage is limited, with no consensus ratings or price targets available, indicating uncertainty for investors.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax COIN Option Income Strategy ETF
CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.
Read more on CONY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
